LifeMD, Inc.
LFMDHealthcareNASDAQHealth Information Services · Last scanned Oct 24, 2026
Scan Results
Daily timeframeLifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. At a $102.8M market cap, LifeMD, Inc. ranks as a micro-cap company within healthcare. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss.
Market Cap
$102.8M
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
5.61
EPS (TTM)
$-0.52
EPS (Fwd)
$0.38
ROE
-515.9%
ROA
-18.9%
Cash
$25.1M
Total Debt
$6.0M
Free CF
-$14.4M
52W Change
-66.2%
Annual Financials
Cash vs Debt
Where LFMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LFMD finished 41.86% below its 150-day moving average ($3.87) and 39.84% below its 200-day moving average ($3.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFMD overbought or oversold?
At the October 20, 2026 close, LFMD's RSI(14) was 18.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LifeMD, Inc. holds $25.1M in cash against $6.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$14.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -515.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $119.0M (2022) to $194.1M (2025), reflecting a 63% increase over the period.
A beta of 1.99 means LFMD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LifeMD, Inc.'s trajectory.